Pacira BioSciences, Inc. has officially completed its merger with Viatris Inc., a significant event that reshapes the company's future and the landscape of the pharmaceutical preparations industry.

This merger, which was finalized on November 17, 2026, is a pivotal moment for Pacira, as it transitions from an independent entity to a wholly owned subsidiary of Viatris. The completion of this merger not only alters Pacira's operational structure but also reflects a broader trend of consolidation within the pharmaceutical sector.

Background

Pacira BioSciences, Inc., identified by the Central Index Key (CIK) 0001396814, operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. The company is listed on the Nasdaq under the ticker symbol PCRX. Pacira has been recognized for its innovative approaches in the pharmaceutical space, particularly in the development of non-opioid pain management solutions.

What the Filing Says

According to the recent SEC filing (accession number 0001140361-26-044354), the merger was executed without a vote from Pacira's stockholders, in accordance with Delaware law. The filing details that each share of Pacira's common stock was converted into the right to receive $36.50 in cash, marking a premium for shareholders. The filing also notes that the merger was facilitated by a tender offer that resulted in approximately 66.46% of shares being validly tendered.

Impact

This merger is expected to impact various stakeholders, including Pacira's employees, shareholders, and customers. For shareholders, the cash payout provides immediate liquidity, while employees may face changes in corporate structure and potential shifts in company culture. Customers may benefit from an expanded product portfolio as Viatris integrates Pacira's offerings into its broader range of pharmaceutical solutions.

What's Next

The filing does not specify what happens next, but typically, such mergers lead to further integration activities and strategic planning sessions as the new entity aligns its operations and objectives.